Aviso: Este site agrega dados públicos oficiais da FDA, ClinicalTrials.gov, PubMed e SEC EDGAR apenas para referência geral. Não constitui aconselhamento médico, diagnóstico, recomendação de tratamento ou aconselhamento de investimento.

Ensaio clínico

TMZ + RT + 5-ALA + LIDU SDT System for Newly Diagnosed Butterfly Glioma

NCT: NCT07862647 · RECRUITING

ID NCTNCT07862647
EstadoRECRUITING
Data de início2026-10-29
Conclusão2028-03-30
SponsorAlpheus Medical, Inc. (INDUSTRY)
First posted
Last updated

Resumo breve

This study is assessing the safety and tolerability of 5-ALA- mediated Porphyrin Metabolite Activation (PoMA) with LIDU ultrasound, in patients who have just been diagnosed with bihemispheric (in both sides of the brain) glioblastoma, sometimes called butterfly glioblastoma, before they complete their standard of care chemotherapy and radiation and after their standard of care chemotherapy and radiation while they are receviing their standard of care adjuvant chemotherapy.

Fonte oficial

Ver no ClinicalTrials.gov →

Dados provenientes da API do ClinicalTrials.gov. Para consultar o estado mais recente, veja o registo oficial.

↑